REGENXBIO (RGNX) Projected to Post Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect REGENXBIO to post earnings of ($0.99) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:00 AM ET.

REGENXBIO Trading Up 5.2%

Shares of RGNX opened at $9.14 on Thursday. REGENXBIO has a 1-year low of $5.03 and a 1-year high of $16.19. The firm’s 50-day moving average price is $11.70 and its 200-day moving average price is $11.41. The firm has a market capitalization of $462.67 million, a price-to-earnings ratio of -2.63 and a beta of 1.08.

Analysts Set New Price Targets

Several analysts have weighed in on RGNX shares. Stifel Nicolaus lifted their price objective on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Chardan Capital dropped their price target on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Robert W. Baird set a $27.00 price target on REGENXBIO in a research note on Tuesday, February 10th. Wall Street Zen lowered REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Finally, Barclays began coverage on shares of REGENXBIO in a report on Tuesday, January 27th. They set an “overweight” rating and a $37.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.80.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its position in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Jane Street Group LLC grew its stake in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock valued at $2,961,000 after purchasing an additional 249,156 shares during the period. Franklin Resources Inc. bought a new stake in shares of REGENXBIO during the 2nd quarter valued at about $239,000. American Century Companies Inc. increased its position in shares of REGENXBIO by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after purchasing an additional 8,487 shares during the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of REGENXBIO in the 2nd quarter worth approximately $87,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.